-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SON-1010 in Mesenchymal Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SON-1010 in Mesenchymal Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SON-1010 in Mesenchymal Tumor Drug Details: SON-1010 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SON-1010 in Sarcomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SON-1010 in Sarcomas report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SON-1010 in Sarcomas Drug Details: SON-1010 is under development for the treatment of...
-
Product Insights
Chemotherapy Induced Peripheral Neuropathy – Drugs In Development, 2023
Global Markets Direct’s, ‘Chemotherapy Induced Peripheral Neuropathy - Drugs In Development, 2023’, provides an overview of the Chemotherapy Induced Peripheral Neuropathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Neuropathy – Drugs In Development, 2023
Global Markets Direct’s, ‘Neuropathy - Drugs In Development, 2023’, provides an overview of the Neuropathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HST-1011 in Castration-Resistant Prostate Cancer (CRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HST-1011 in Castration-Resistant Prostate Cancer (CRPC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HST-1011 in Castration-Resistant Prostate Cancer (CRPC) Drug Details: HST-1011...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SON-1010 in Head And Neck Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SON-1010 in Head And Neck Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SON-1010 in Head And Neck Cancer Drug Details: SON-1010 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SV-102 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SV-102 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SV-102 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug Details:SV-102 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BMS-986406 in Metastatic Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BMS-986406 in Metastatic Renal Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.BMS-986406 in Metastatic Renal Cell Carcinoma Drug Details:BMS-986406 is under development...